EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of Epstein-Barr virus -associated lymphomas and PTLD using Arginine Butyrate to induce viral TK gene expression Initial findings of a phase I/II trial



Treatment of Epstein-Barr virus -associated lymphomas and PTLD using Arginine Butyrate to induce viral TK gene expression Initial findings of a phase I/II trial



Blood 94(10 SUPPL 1 PART 1): 523a, Nov 15




(PDF 0-2 workdays service: $29.90)

Accession: 035980399

Download citation: RISBibTeXText



Related references

Phase I/II trial of arginine butyrate to induce viral TK gene expression in Epstein-Barr virus -associated lymphomas. Proceedings of the American Association for Cancer Research Annual Meeting (41): 544, March, 2000

Phase I/II trial of Arginine Butyrate and ganciclovir in Epstein-Barr virus-associated lymphoid malignancies. Journal of Clinical Oncology 24(18_suppl): 7542-7542, 2016

A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 109(6): 2571-2578, 2006

Molecular size variation of epstein barr virus induced nuclear antigen is determined by the epstein barr viral genome studies on sublines of epstein barr virus negative lymphomas converted with different epstein barr virus substrains and on somatic hybrids. Intervirology 22(2): 85-96, 1984

Arginine butyrate-induced susceptibility to ganciclovir in Epstein-Barr virus -associated lymphomas. Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 411-412, 1996

A survey of Epstein-Barr virus gene expression in sporadic non-Hodgkin's lymphomas. Detection of Epstein-Barr virus in a subset of peripheral T-cell lymphomas. American Journal of Pathology 140(6): 1315-1325, 1992

Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transplant Infectious Disease 3(3): 177-185, 2001

Development of cell systems to study viral gene transcription at the initial phase of Epstein-Barr virus infection. Virus Genes 1(1): 73-82, 1987

Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression. Journal of Clinical Oncology 11(9): 1674-1681, 1993

Epstein-Barr virus (EBV) genotypes among human immunodeficiency virus (HIV)-related B-cell lymphomas and B-cell post-transplant lymphoproliferative disorders (B-PTLD)--late-onset lymphomas, especially in the HIV setting, are associated with type-B-EBV. European Journal of Haematology 85(3): 227-230, 2010

Restricted expression of latency-associated viral genes and production of viral IL-10 in Epstein-Barr virus-related NK/T-cell lymphomas. Journal of Dermatological Science 23(3): 198, August, 2000

T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. New England Journal of Medicine 318(12): 733-741, 1988

Viral genotypes and p53 expression in Epstein-Barr virus-associated primary malignant lymphomas of the intestines. Human Pathology 30(10): 1146-1152, 1999

Gene therapy strategies for treating Epstein-Barr virus-associated lymphomas: comparison of two different Epstein-Barr virus-based vectors. Human Gene Therapy 9(8): 1131-1141, 1998